New chemo combo could improve outcomes for stomach cancer patients

NCT ID NCT07366528

Recruiting now Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether a chemotherapy combination of oxaliplatin plus S-1 works as well as or better than docetaxel plus S-1 for stage III gastric cancer patients who have had surgery. About 387 adults aged 18 to 80 will be randomly assigned to one of the two treatments. The main goal is to see how many patients remain cancer-free after three years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: oxaliplatin plus S-1 or docetaxel plus S-1
What this could lead to: If successful, this could identify a more effective or less toxic chemotherapy option for stage III gastric cancer patients after surgery.
What could go wrong: This is a non-inferiority trial, so the new combo may not be better than the standard. Side effects from chemotherapy are expected and can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADJUVANT CHEMOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADJUVANT CHEMOTHERAPY DOCETAXEL GASTRIC CANCER (GC) OXALIPLATIN STAGE 3 CANCER

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
NOT_YET_RECRUITING

Shanghai, China
Renji Hospital
NOT_YET_RECRUITING

Shanghai, China
Ruijin Hospital
RECRUITING

Shanghai, China
Shanghai Tenth People's Hospital
NOT_YET_RECRUITING

Shanghai, China
Yuebei People's Hospital
NOT_YET_RECRUITING

Shaoguan, Guandong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.